The current status of interventions aiming at reducing sudden cardiac death in dialysis patients

European Heart Journal

Volumn 30, Issue 13, 2009, Pages 1559-1564

  De Bie, Mihály K ^a   Van Dam, Bastiaan ^b   Gaasbeek, André ^a   Van Buren, Marjolijn ^c   Van Erven, Lieselot ^a   Bax, Jeroen J ^a   Schalij, Martin J ^a   Rabelink, Ton J ^a   Jukema, J Wouter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Location Alkmaar   (Netherlands)

^c Haga Hospital   (Netherlands)

Author keywords

Dialysis; Implantable cardioverter defibrillator therapy; Ischaemic heart disease; Leftventricular hypertrophy; Sudden cardiac death

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIALYSIS FLUID; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANEMIA; ARTIFICIAL KIDNEY; DEFIBRILLATOR; GLUCOSE BLOOD LEVEL; HEART ARREST; HEART DEATH; HEART INFARCTION; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SUDDEN DEATH;

ADRENERGIC BETA-ANTAGONISTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ERYTHROPOIETIN, RECOMBINANT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; MYOCARDIAL REVASCULARIZATION; RENAL DIALYSIS; RISK FACTORS;

EID: 67650077961     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp185     Document Type: Review

References (70)

1. U.S. Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007.
2. Ansell D, Feehally J, Feest TG, Tomson C, Williams AJ, Warwick G. UK Renal Registry Report 2007. Bristol, UK: UK Renal Registry; 2007.
3. Oppe M, Treur MJ, Barendregt W, de Charro FT. Statistisch Verslag 2007 deel 1. Rotterdam: Stichting RENINE; 2007.
4. U.S. Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes ofHealth, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
5. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Effectofdialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-2019.
6. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248.
7. Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G. Characteristics of sudden death in hemodialysis patients. Kidney Int 2006;69:2268-2273.
8. Ritz E, Amann K, Tornig J, Schwarz U, Stein G. Some cardiac abnormalities in renal failure. Adv Nephrol Necker Hosp 1997;27:85-103.
9. Amann K, Buzello M, Simonaviciene A, Miltenberger-Miltenyi G, Koch A, Nabokov A, Gross ML, Gless B, Mall G, Ritz E. Capillary/myocyte mismatch in the heart in renal failurea role for erythropoietin? Nephrol Dial Transplant 2000;15:964-969.
10. Amann K, Rychlik I, Miltenberger-Milteny G, Ritz E. Left ventricular hypertrophy in renal failure. Kidney Int Suppl 1998;68:S78-S85.
11. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 1997;4:212-224.
12. Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, Imai R, Okino K, Iwamoto N, Takahashi H, Ono T. Sympathetic overactivity and sudden cardiac death among hemodialysis patients with left ventricular hypertrophy. Int JCardiol 2009.
13. Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int 2007; 71:153 -158.
14. Collins AJ, Weinhandl E, Snyder JJ, Chen SC, Gilbertson D. Comparison and survival of hemodialysis and peritoneal dialysis in the elderly. Semin Dial 2002;15:98-102.
15. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors ofthe rate ofdecline ofresidual renal function in incident dialysis patients. Kidney Int 2002;62:1046-1053.
16. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl JMed 1992;327:1912-1918.
17. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998;11: 723-728.
18. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002;105:1354-1359.
19. Furgeson SB, Chonchol M. Beta-blockade in chronic dialysis patients. Semin Dial 2008;21:43-48.
20. Zuanetti G, Maggioni AP, Keane W, Ritz E. Nephrologists neglect administration of beta-blockers to dialysed diabetic patients. Nephrol Dial Transplant 1997;12:2497-2500.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
22. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di MC, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J2008;29:2909-2945.
23. Goldstein S, Hjalmarson A. The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF Trial. Clin Cardiol 1999;22(Suppl. 5): V30-V35.
24. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002;62:1784-1790.
25. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di BA, Cittadini A, Russo PE, Golino P, Calabro R. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. JAm Coll Cardiol 2003;41:1438-1444.
26. Pun PH, Lehrich RW, Smith SR, Middleton JP. Predictors ofsurvival after cardiac arrest in outpatient hemodialysis clinics. Clin JAm Soc Nephrol 2007;2:491 -500.
27. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004;164:2465-2471.
28. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J2000;21:2071 -2078.
29. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl JMed 1996;335:1933-1940.
30. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl JMed 2002;346:877-883.
31. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-1890.
32. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, vidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237.
33. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterollowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278.
34. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ2008;336:645-651.
35. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl JMed 2007;357:2248-2261.
36. Foley RN, Parfrey PS, Harnett JD, Kent GM, MurrayDC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
37. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989;36:286-290.
38. Paoletti E, Specchia C, Di MG, Bellino D, Damasio B, Cassottana P, Cannella G. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004;19:1829-1834.
39. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995;47:186-192.
40. Frank H, Heusser K, Hoffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. Kidney Int 2004;66:832-840.
41. Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/ hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006;47:24-36.
42. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2006; CD003967.
43. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-S154.
44. Owen WFJr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1001-1006.
45. Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJ, Agodoa LY, Port FK. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am JKidney Dis 1999;33:349-355.
46. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002;13:1061-1066.
47. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM. The dose of hemodialysis and patient mortality. Kidney Int 1996;50:550-556.
48. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortalityin the DOPPS. KidneyInt2006;69:1222-1228.
49. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. Kidney Int 2006;69:1229-1236.
50. Leypoldt JK. Solute fluxes in different treatment modalities. Nephrol Dial Transplant 2000;15(Suppl. 1):3-9.
51. Vanholder R, De SR, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, scamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
52. Canaud B, Bragg-Gresham JL, Marshall MR, Desmeules S, Gillespie BW, Depner T, Klassen P, Port FK. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int 2006;69:2087-2093.
53. CheungAK,Levin NW,GreeneT,AgodoaL,BaileyJ,BeckG,ClarkW,LeveyAS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. JAm SocNephrol2003;14:3251-3263.
54. van der Weerd NC, Penne EL, van den Dorpel MA, Grooteman MP, Nube MJ, Bots ML, ter Wee PM, Blankestijn PJ. Haemodiafiltration: promise for the future? Nephrol Dial Transplant 2008;23:438-443.
55. DePalma JR, Pecker EA, Gordon A, Maxwell MH. A new compact automatic home hemodialysis system. Trans Am Soc Artif Intern Organs 1968;14:152-159.
56. Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR, Tonelli M, Donnelly S, Friedrich MG, Kumar A, Mahallati H, Hemmelgarn BR, Manns BJ. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007;298:1291-1299.
57. Kjellstrand CM, Buoncristiani U, Ting G, Traeger J, Piccoli GB, Sibai-Galland R, Young BA, Blagg CR. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. Nephrol Dial Transplant 2008.
58. Myerburg RJ, Castellanos A. Cardiac arrest and sudden death. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saun- ders; 1997. p742-779.
59. Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, Levey AS. Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis 2002;39:146 -153.
60. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS. Cardiac diseases in maintenance hemodialysispatients: results ofthe HEMO Study. KidneyInt2004;65: 2380-2389.
61. FoleyRN,ParfreyPS,SarnakMJ.Clinicalepidemiologyofcardiovasculardiseasein chronic renal disease. Am JKidneyDis1998;32:S112-S119.
62. Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J2006;152:558-564.
63. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA. Survival after coronary revascularization among patients with kidney disease. Circulation 2004;110:1890-1895.
64. Herzog CA, Strief JW, Collins AJ, Gilbertson DT. Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention? Nephrol Dial Transplant 2008.
65. HerzogCA,Li S,WeinhandlED,StriefJW,CollinsAJ,GilbertsonDT.Survivalof dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005;68:818-825.
66. HreybeH,EzzeddineR,BediM,BarringtonW,BazazR,GanzLI,JainS,NgwuO, London B, Saba S. Renal insufficiency predicts the time to first appropriate defi- brillator shock. Am Heart J2006;151:852-856.
67. Robin J, Weinberg K, Tiongson J, Carnethon M, Reddy M, Ciaccio C, Quadrini M, Hsu J, Fan J, Choi P, Kadish A, Goldberger J, Passman R. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter- defibrillator recipients. Heart Rhythm 2006;3:1196-1201.
68. Wase A, Basit A, Nazir R, Jamal A, Shah S, Khan T, Mohiuddin I, White C, Saklayen M, McCullough PA. Impact of chronic kidney disease upon survival among implantable cardioverter-defibrillator recipients. J Interv Card Electrophysioi 2004;11:199-204.
69. Dasgupta A, Montalvo J, Medendorp S, Lloyd-Jones DM, Ghossein C, Goldberger J, Passman R. Increased complication rates ofcardiac rhythm manage- mentdevices in ESRD patients. Am JKidneyDis2007;49:656-663.
70. de Bie MK, Lekkerkerker JC, van Dam B, Gaasbeek A, van Buren M, Putter H, van Erven L, Bax JJ, Schalij MJ, Rabelink TJ, Jukema JW. Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Triala prospective pilot study. Curr Med Res Opin 2008;24:2151-2157.